|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Cancer Institute (NCI) |
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001210 |
Purpose
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.
| Condition |
|
HIV Infections Healthy |
| MedlinePlus related topics: | AIDS |
| Study Type: | Observational |
| Official Title: | Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines |
| Estimated Enrollment: | 60 |
| Study Start Date: | November 1986 |
| Estimated Study Completion Date: | September 2000 |
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria for the at risk group will be a statement from the donor that he is an active homosexual or bisexual.
Homosexual donors must not have AIDS.
Contacts and Locations
More Information
| Study ID Numbers: | 860199, 86-C-0199 |
| First Received: | November 3, 1999 |
| Last Updated: | March 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001210 |
| Health Authority: | United States: Federal Government |
|
|
|
|